Alpha1-Antichymotrypsin Level in Cerebrospinal Fluid Is Closely Associated with Late Onset Alzheimer's Disease.
Authors:
Open Access
- 1 January 1995
- journal article
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 34 (6) , 481-484
Abstract
The levels of α1-antichymotrypsin (ACT) in cerebrospinal fluid (CSF) from 66 sporadic Alzheimer's disease (AD) patients and 54 normal controls were measured by enzyme immunoassay and compared. There was no correlation (r=0.259, n=54) between the ACT level and normal aging. The levels of ACT were significantly higher in the total AD group (p<0.01) than in the normal control group. Dividing AD patients into early onset AD (n=27) and late onset AD groups (n=39), the mean level of CSF ACT in the late onset AD group was significantly higher than that in the normal control group (p<0.001) and that in the early onset AD group (p<0.01). Thus, the level of ACT in CSF is closely associated with late onset AD. (Internal Medicine 34: 481-484, 1995)Keywords
This publication has 6 references indexed in Scilit:
- Morphological and Biochemical Analyses of Amyloid Plaque Core Proteins Purified from Alzheimer Disease Brain TissueJournal of Neurochemistry, 1993
- α1‐Antichymotrypsin as a possible biochemical marker for Alzheimer‐type dementiaAnnals of Neurology, 1990
- Down patients: Extracellular preamyloid deposits precede neuritic degeneration and senile plaquesNeuroscience Letters, 1989
- Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's diseaseCell, 1988
- Functional Staging of Dementia of the Alzheimer TypeAnnals of the New York Academy of Sciences, 1984
- HUMAN PLASMA PROTEINASE INHIBITORSAnnual Review of Biochemistry, 1983